## Katia Mc Verhamme

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1515165/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence, Incidence, and Lifetime Risk for the Development of COPD in the Elderly. Chest, 2009, 135, 368-377.	0.4	130
2	Adverse drug reactionâ€related hospitalisations: a populationâ€based cohort study. Pharmacoepidemiology and Drug Safety, 2008, 17, 365-371.	0.9	128
3	Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ, The, 0, , n1435.	3.0	112
4	Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study. Lancet Infectious Diseases, The, 2022, 22, 1142-1152.	4.6	60
5	The influence of age and gender on sensitization to aeroâ€allergens. Pediatric Allergy and Immunology, 2007, 18, 671-678.	1.1	50
6	Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia, 2010, 51, 789-796.	2.6	44
7	Prevalence and incidence of, and risk factors for chronic cough in the adult population: the Rotterdam Study. ERJ Open Research, 2020, 6, 00300-2019.	1.1	44
8	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 578-588.e2.	2.0	39
9	Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ: British Medical Journal, 2006, 333, 330.	2.4	35
10	Asthma and its comorbidities in middle-aged and older adults; the Rotterdam Study. Respiratory Medicine, 2018, 139, 6-12.	1.3	32
11	Background rates of five thrombosis with thrombocytopenia syndromes of special interest for <scp>COVID</scp> â€19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiology and Drug Safety, 2022, 31, 495-510	0.9	32
12	Databases for pediatric medicine research in Europe—assessment and critical appraisal. Pharmacoepidemiology and Drug Safety, 2008, 17, 1155-1167.	0.9	31
13	Multinational cohort study of mortality in patients with asthma and severe asthma. Respiratory Medicine, 2020, 165, 105919.	1.3	31
14	EU postmarket surveillance plans for medical devices. Pharmacoepidemiology and Drug Safety, 2019, 28, 1155-1165.	0.9	27
15	17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2083-2088.	2.7	22
16	The interrelatedness of chronic cough and chronic pain. European Respiratory Journal, 2021, 57, 2002651.	3.1	19
17	Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries. BMJ Open, 2021, 11, e047258.	0.8	18
18	Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use. European Respiratory Journal, 2021, 57, 2003388.	3.1	17

KATIA MC VERHAMME

#	Article	IF	CITATIONS
19	Study designs in paediatric pharmacoepidemiology. European Journal of Clinical Pharmacology, 2011, 67, 67-74.	0.8	16
20	Trends of prescribing antimicrobial drugs for urinary tract infections in primary care in the Netherlands: a population-based cohort study. BMJ Open, 2019, 9, e027221.	0.8	15
21	Blockchain technology applications to postmarket surveillance of medical devices. Expert Review of Medical Devices, 2020, 17, 1123-1132.	1.4	13
22	The interrelationship of chronic cough and depression: a prospective population-based study. ERJ Open Research, 2022, 8, 00069-2022.	1.1	12
23	A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid. International Journal of COPD, 2022, Volume 17, 545-558.	0.9	11
24	FCER2 T2206C variant associated with FENO levels in asthmatic children using inhaled corticosteroids: The PACMAN study. Clinical and Experimental Allergy, 2019, 49, 1429-1436.	1.4	10
25	Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 656-664.	1.3	9
26	Overview of the <scp>European postâ€authorisation study</scp> register postâ€authorization studies performed in Europe from September 2010 to December 2018. Pharmacoepidemiology and Drug Safety, 2022, 31, 689-705.	0.9	9
27	Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study. ERJ Open Research, 2022, 8, 00628-2021.	1.1	9
28	Sarcopenia in older people with chronic airway diseases: the Rotterdam study. ERJ Open Research, 2021, 7, 00522-2020.	1.1	8
29	Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands. Journal of the Peripheral Nervous System, 2022, 27, 182-188.	1.4	7
30	Current needs in pediatric pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2016, 25, 738-742.	0.9	5
31	Effectiveness of a 6-Month Isoniazid on Prevention of Incident Tuberculosis Among People Living with HIV in Eritrea: A Retrospective Cohort Study. Infectious Diseases and Therapy, 2022, 11, 559-579.	1.8	5
32	Pharmacoepidemiology in pediatrics: Needs, challenges and future directions for research. Therapie, 2018, 73, 151-156.	0.6	4
33	Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database. European Urology Focus, 2022, 8, 1424-1432.	1.6	4
34	Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe. Journal of Asthma, 2023, 60, 76-86.	0.9	4
35	Impact of different assumptions on estimates of childhood diseases obtained from health care data: A <i>retrospective cohort study</i> . Pharmacoepidemiology and Drug Safety, 2018, 27, 612-620.	0.9	3
36	Choice of time period to identify confounders for propensity score matching, affected the estimate: a retrospective cohort study of drug effectiveness in asthmatic children. Journal of Clinical Epidemiology, 2018, 101, 107-115.e3.	2.4	2

#	Article	IF	CITATIONS
37	Effect of β-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam Study. ERJ Open Research, 2021, 7, 00624-2020.	1.1	2
38	NEW QUALITY INDICATORS FOR PAEDIATRIC ANTIBIOTIC PRESCRIBING IN PRIMARY CARE: A POPULATION BASED COHORT STUDY IN THE UNITED KINGDOM, ITALY AND THE NETHERLANDS FROM 1995–2010. Archives of Disease in Childhood, 2016, 101, e1.73-e1.	1.0	1
39	Incidence and predictors of asthma exacerbations in middle-aged and older adults: the Rotterdam Study. ERJ Open Research, 2021, 7, 00126-2021.	1.1	1